Nucleic acid amplification technology screening for hepatitis C virus and human immunodeficiency virus for blood donations

Saudi Medical Journal

Volumn 27, Issue 6, 2006, Pages 781-787

  Bamaga, Mohammad S ^a   Bokhari, Fawzi F ^a   Aboud, AbdulRahaman M ^a   Al Malki, Meshal ^a   Alenzi, Faris Q ^b  

^a AL HADA ARMED FORCES HOSPITAL   (Saudi Arabia)

^b IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS DNA; VIRUS RNA;

ARTICLE; AUTOANALYZER; AUTOMATION; BLOOD ANALYSIS; BLOOD DONOR; BLOOD SAMPLING; BLOOD TRANSFUSION; CONTROLLED STUDY; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; INFECTION RISK; NONHUMAN; NUCLEIC ACID AMPLIFICATION; QUALITATIVE ANALYSIS; RELIABILITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK REDUCTION; RNA ANALYSIS; RNA EXTRACTION; SAUDI ARABIA; SERODIAGNOSIS; VIRUS DETECTION; VIRUS STRAIN; VIRUS TRANSMISSION;

BLOOD DONORS; DISEASE TRANSMISSION; DISEASE TRANSMISSION, INFECTIOUS; HEPACIVIRUS; HIV-1; HUMANS; MASS SCREENING; NUCLEIC ACID AMPLIFICATION TECHNIQUES; REPRODUCIBILITY OF RESULTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, VIRAL; SAUDI ARABIA;

EID: 33746395943     PISSN: 03795284     EISSN: 03795284     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. El-Hazmi MM. Prevalence of HBV, HCV, HIV-1, 2 and HTLV-I/II infections among blood donors in a teaching hospital in the Central region of Saudi Arabia. Saudi Med J 2004; 25: 26-33.
2. Goodnough LT, Brecher ME, Kanter MH, AuBuchon JP. Transfusion medicine. First of two parts - blood hunsfusion. N Engl J Med 1999; 340: 438-447.
3. Gaines HM, von Sydow A, Sonnerborg J, Albert J, Czajkowski J, Pehrson PO, et al. Antibody response in primary human immunodeficiency virus infection. Lancet 1987; 1: 1249-1253.
4. Allain JR Transfusion risks of yesterday and of today. Transfus Clin Biol 2003; 10: 1-5.
5. Eiras A, Sauleda S, Planelles D, Sedeno M, Ibarra A, Vesga MA, et al. HCV screening in blood donations using RT-PCR in mini-pool: the experience in Spain after routine use for 2 years. Transfusion 2003; 43: 713-720.
6. Gessoni G, Barin P, Valverde S, Giacomini A, Di Natale C, Orlandini E, et al. Biological qualification of blood units: considerations about the effects of sample's handling and storage on stability of nucleic acids. Transfus Apher Sci 2004; 30: 197-203.
7. Yang Y, Lamendola MH, Mendoza M, Xu D, Nguyen M, Yeh S, et al. Performance characteristics of the COBAS AmpliScreen HIV-1 test, version 1.5, an assay designed for screening plasma mini-pools. Transfusion 2001; 41: 643-651.
8. Roth WK, Seifried E. Yield and future issues of nucleic acid testing. Transfus Clin Biol 2001; 8: 282-284.
9. Tomono T, Murokawa H, Minegishi K, Yamanaka R, Lizuka HY, Miyamoto M, et al. Status of NAT screening for HCV, HIV and HBV. experience in Japan. Dev Biol (Basel) 2002; 108: 29-39.
10. Araujo F, Henriques I, Monteiro F, Meireles E, Cruz A, Tavares G, et al. Evaluation of NucliSens-AmpliScreen methodology to detect subtypes G of HIV-1 and 4c/4d of HCV in the screening of blood donors. Transfus Clin Biol 2005; 12: 331-335.
11. Koppelman MH, Sjerps MC, Reesink HW, Cuypers HT. Evaluation of COBAS AmpliPrep nucleic acid extraction in conjunction with COBAS AmpliScreen HBV DNA, HCV RNA and HIV-1 RNA amplification and detection. Vox Sang 2005; 89: 193-200.
12. Velati C, Fomiatti L, Baruffi L, Romano L, Zanetti A. Impact of nucleic acid amplification technology (NAT) in Italy in the three years following implementation (2001-2003). Euro Surveill 2005; 10: 12-14.